EVX B1
Alternative Names: EVX-B1Latest Information Update: 01 Aug 2023
At a glance
- Originator Evaxion Biotech
- Class Bacterial vaccines; Protein vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
Most Recent Events
- 31 Jul 2023 Immunogenicity data from a preclinical studies in Methicillin-resistant Staphylococcus aureus infections released by Evaxion Biotech
- 31 Jul 2023 Evaxion Biotech plans a clinical trial for Methicillin-resistant Staphylococcus aureus infections
- 10 Aug 2022 Evaxion Biotech announces intention to submit phase I regulatory filings for Skin and soft tissue infections in second half of 2022 (Date)